Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GEORGE M LEWITT

Allopathic & Osteopathic Physicians Dermatology

NPI
1902031313
CMS profile
221538
Location
NORTHBROOK, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$785,019.85

714 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 15; records 51–100 of 714 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GEORGE M LEWITT

NPI 1902031313 · CMS profile ID 221538

Allopathic & Osteopathic Physicians / Dermatology

NORTHBROOK, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 15; records 51–100 of 714 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1902031313?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GEORGE M LEWITT, NPI 1902031313, CMS profile ID 221538. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 15; records 51–100 of 714 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1902031313?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). GEORGE M LEWITT, NPI 1902031313, CMS profile ID 221538. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 15; records 51–100 of 714 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1902031313?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
GEORGE M LEWITT, NPI 1902031313, CMS profile ID 221538, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 15; records 51–100 of 714 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1902031313?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

714 matching records · $785,019.85 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 714 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 714.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $196.0011/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104193766 CMS
Lilly USA, LLC $5.9011/20/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155955948 CMS
Lilly USA, LLC $127.1611/20/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155959578 CMS
Janssen Biotech, Inc. $65.0011/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078599066 CMS
Janssen Biotech, Inc. $16.5211/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078599110 CMS
Janssen Biotech, Inc. $190.6411/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078599138 CMS
Janssen Biotech, Inc. $3.5111/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078599281 CMS
Janssen Biotech, Inc. $5,775.0011/18/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078599233 CMS
Lilly USA, LLC $23.5011/18/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155955954 CMS
Lilly USA, LLC $3,200.0011/18/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1155958542 CMS
Lilly USA, LLC $1,200.0011/18/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1155959618 CMS
UCB, Inc. $28.4611/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143067713 CMS
Dermavant Sciences, Inc. $8,140.0011/16/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127897963 CMS
Dermavant Sciences, Inc. $246.3811/16/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127897967 CMS
Dermavant Sciences, Inc. $46.8611/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127897971 CMS
Dermavant Sciences, Inc. $34.5611/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127897975 CMS
Dermavant Sciences, Inc. $73.6211/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127897978 CMS
Dermavant Sciences, Inc. $41.7611/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127897982 CMS
ABBVIE INC. $625.9511/15/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104193764 CMS
Dermavant Sciences, Inc. $3,200.0011/14/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127897959 CMS
Lilly USA, LLC $443.3911/14/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135006259 CMS
UCB, Inc. $40.0011/14/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143067711 CMS
Arcutis Biotherapeutics, Inc. $3,000.0011/13/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121048121 CMS
Dermavant Sciences, Inc. $149.8711/13/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127897952 CMS
Dermavant Sciences, Inc. $89.3811/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127897955 CMS
E.R. Squibb & Sons, L.L.C. $19.9811/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101626096 CMS
Lilly USA, LLC $291.7911/13/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1134999394 CMS
UCB, Inc. $1,660.0011/12/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143067709 CMS
Dermavant Sciences, Inc. $22.9111/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127897948 CMS
PFIZER INC. $4,000.0011/11/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131159661 CMS
Dermavant Sciences, Inc. $631.0011/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127897944 CMS
PFIZER INC. $79.1811/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131086689 CMS
Arcutis Biotherapeutics, Inc. $483.8011/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121048123 CMS
Arcutis Biotherapeutics, Inc. $22.8311/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121048127 CMS
Incyte Corporation $468.0511/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141247582 CMS
ABBVIE INC. $22.1111/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104171180 CMS
Arcutis Biotherapeutics, Inc. $10.5011/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121048101 CMS
ABBVIE INC. $168.0011/04/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103136883 CMS
ABBVIE INC. $3,200.0011/04/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103136885 CMS
ABBVIE INC. $84.1811/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104193762 CMS
E.R. Squibb & Sons, L.L.C. $3,500.0011/04/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101626088 CMS
PFIZER INC. $18.8811/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131187627 CMS
UCB, Inc. $148.5411/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143067707 CMS
Janssen Biotech, Inc. $57.9311/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078599001 CMS
Janssen Biotech, Inc. $38.3011/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078599034 CMS
Janssen Biotech, Inc. $38.7311/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078599070 CMS
Dermavant Sciences, Inc. $13.8411/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127897940 CMS
Janssen Biotech, Inc. $231.8611/01/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078599027 CMS
Janssen Biotech, Inc. $149.6911/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078599277 CMS
Janssen Biotech, Inc. $298.6411/01/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078599357 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $194,518.70 449
PY2020 $168,250.40 248
PY2021 $182,420.16 226
PY2022 $286,022.99 316
PY2023 $598,015.94 575
PY2024 $785,019.85 714
PY2025 $773,103.72 673

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $495,509.49 55
PY2024 Recipient $104.58 1
PY2024 Principal investigator $434,117.42 79
PY2023 Recipient $7,463.00 1
PY2023 Principal investigator $79,353.85 34
PY2022 Principal investigator $4,148.00 1
PY2021 Principal investigator $905.48 1
PY2019 Principal investigator $4,835.80 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

55 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $3,537.36 12/31/2025 Non-covered Recipient Entity
ARANO LLC
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects with Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy No dispute reported 06/30/2026 1202533751
Principal investigator 1 ABBVIE INC. $7,950.00 12/04/2025 Non-covered Recipient Entity
DENOVA RESEARCH
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202526994
Principal investigator 1 ABBVIE INC. $5,785.50 12/04/2025 Non-covered Recipient Entity
ARANO PLLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202528156
Principal investigator 1 ABBVIE INC. $5,689.20 12/04/2025 Non-covered Recipient Entity
DENOVA RESEARCH
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202528170
Principal investigator 1 Incyte Corporation $1,436.10 12/04/2025 Non-covered Recipient Entity
ILLINOIS DERMATOLOGY INSTITUTE THE CHICAGO LOOP
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240538980
Principal investigator 1 Incyte Corporation $50.00 12/01/2025 Non-covered Recipient Entity
DENOVA RESEARCH
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240525619
Principal investigator 1 Incyte Corporation $1,211.40 11/25/2025 Non-covered Recipient Entity
ILLINOIS DERMATOLOGY INSTITUTE THE CHICAGO LOOP
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240538975
Principal investigator 1 ABBVIE INC. $4,630.80 11/04/2025 Non-covered Recipient Entity
ARANO PLLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202520629
Principal investigator 1 ABBVIE INC. $5,760.00 11/04/2025 Non-covered Recipient Entity
DENOVA RESEARCH
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202520631
Principal investigator 1 Incyte Corporation $1,211.40 10/29/2025 Non-covered Recipient Entity
ILLINOIS DERMATOLOGY INSTITUTE THE CHICAGO LOOP
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240538970
Principal investigator 1 ABBVIE INC. $3,985.00 10/09/2025 Non-covered Recipient Entity
DENOVA RESEARCH
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202515551
Principal investigator 1 ABBVIE INC. $6,888.60 10/09/2025 Non-covered Recipient Entity
DENOVA RESEARCH
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202515553
Principal investigator 1 ABBVIE INC. $5,038.80 10/09/2025 Non-covered Recipient Entity
DENOVA RESEARCH
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202515555
Principal investigator 1 ABBVIE INC. $12,600.00 10/09/2025 Non-covered Recipient Entity
ARANO PLLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202515557
Principal investigator 1 Incyte Corporation $6,000.00 10/09/2025 Non-covered Recipient Entity
DENOVA RESEARCH
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240525610
Principal investigator 1 Incyte Corporation $1,500.00 10/09/2025 Non-covered Recipient Entity
DENOVA RESEARCH
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240525614
Principal investigator 1 Novartis Pharmaceuticals Corporation $38,269.13 10/08/2025 Non-covered Recipient Entity
ILLINOIS DERMATOLOGY INSTITUTE, LLC
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S No dispute reported 06/30/2026 1190308022
Principal investigator 1 Incyte Corporation $1,650.60 09/23/2025 Non-covered Recipient Entity
ILLINOIS DERMATOLOGY INSTITUTE THE CHICAGO LOOP
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240538960
Principal investigator 1 ABBVIE INC. $310.17 09/22/2025 Non-covered Recipient Entity
DENOVA RESEARCH
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202511718
Principal investigator 1 Incyte Corporation $4,854.60 09/12/2025 Non-covered Recipient Entity
ILLINOIS DERMATOLOGY INSTITUTE THE CHICAGO LOOP
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240538963
Principal investigator 1 ABBVIE INC. $900.00 09/11/2025 Non-covered Recipient Entity
DENOVA RESEARCH
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202510600
Principal investigator 1 ABBVIE INC. $494.00 09/04/2025 Non-covered Recipient Entity
DENOVA RESEARCH
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202508496
Principal investigator 1 Incyte Corporation $2,278.80 09/04/2025 Non-covered Recipient Entity
ILLINOIS DERMATOLOGY INSTITUTE THE CHICAGO LOOP
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240538966
Principal investigator 1 ABBVIE INC. $8,958.60 09/03/2025 Non-covered Recipient Entity
DENOVA RESEARCH
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202507165
Principal investigator 1 ABBVIE INC. $8,431.20 09/03/2025 Non-covered Recipient Entity
DENOVA RESEARCH
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202507167
Principal investigator 1 Incyte Corporation $1,718.10 08/26/2025 Non-covered Recipient Entity
ILLINOIS DERMATOLOGY INSTITUTE THE CHICAGO LOOP
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240538956
Principal investigator 1 Janssen Research & Development, LLC $4,240.50 08/25/2025 Non-covered Recipient Entity
DENOVA RESEARCH
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1175337555
Principal investigator 1 Janssen Research & Development, LLC $6,000.00 08/18/2025 Non-covered Recipient Entity
DENOVA RESEARCH
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1175337578
Principal investigator 1 ABBVIE INC. $2,293.60 08/06/2025 Non-covered Recipient Entity
DENOVA RESEARCH
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202502362
Principal investigator 1 ABBVIE INC. $14,467.20 08/05/2025 Non-covered Recipient Entity
DENOVA RESEARCH
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202501176
Principal investigator 1 ABBVIE INC. $7,337.40 08/05/2025 Non-covered Recipient Entity
DENOVA RESEARCH
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202501224
Principal investigator 1 Eli Lilly and Company $5,940.79 07/17/2025 Non-covered Recipient Entity
DENOVA RESEARCH
A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) No dispute reported 06/30/2026 1187881692
Principal investigator 1 Eli Lilly and Company $4,500.00 07/15/2025 Non-covered Recipient Entity
DENOVA RESEARCH
A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) No dispute reported 06/30/2026 1187881342
Principal investigator 1 ABBVIE INC. $6,754.80 07/02/2025 Non-covered Recipient Entity
DENOVA RESEARCH
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202494025
Principal investigator 1 ABBVIE INC. $6,817.80 07/02/2025 Non-covered Recipient Entity
DENOVA RESEARCH
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202496683
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 06/30/2025 Non-covered Recipient Entity
DENOVA RESEARCH
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175337571
Principal investigator 1 ABBVIE INC. $8,346.00 06/03/2025 Non-covered Recipient Entity
DENOVA RESEARCH
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202488309
Principal investigator 1 ABBVIE INC. $1,086.60 06/03/2025 Non-covered Recipient Entity
DENOVA RESEARCH
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202488311
Principal investigator 1 Eli Lilly and Company $64,967.65 06/03/2025 Non-covered Recipient Entity
DENOVA RESEARCH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC HAND AND FOOT DERMATITIS No dispute reported 06/30/2026 1187882468
Principal investigator 1 ABBVIE INC. $1,993.60 05/07/2025 Non-covered Recipient Entity
DENOVA RESEARCH
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202483931
Principal investigator 1 ABBVIE INC. $15,487.20 05/07/2025 Non-covered Recipient Entity
DENOVA RESEARCH
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202483933
Principal investigator 1 ABBVIE INC. $14,436.00 05/06/2025 Non-covered Recipient Entity
DENOVA RESEARCH
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202482175
Principal investigator 1 Eli Lilly and Company $4,938.08 04/23/2025 Non-covered Recipient Entity
DENOVA RESEARCH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC HAND AND FOOT DERMATITIS No dispute reported 06/30/2026 1187879727
Principal investigator 1 ABBVIE INC. $9,490.80 04/03/2025 Non-covered Recipient Entity
DENOVA RESEARCH
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202472066
Principal investigator 1 ABBVIE INC. $13,959.60 04/03/2025 Non-covered Recipient Entity
DENOVA RESEARCH
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202472082
Principal investigator 1 ABBVIE INC. $2,990.00 04/03/2025 Non-covered Recipient Entity
DENOVA RESEARCH
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202472775
Principal investigator 1 ABBVIE INC. $5,084.40 03/07/2025 Non-covered Recipient Entity
DENOVA RESEARCH
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202459845
Principal investigator 1 ABBVIE INC. $7,990.80 03/07/2025 Non-covered Recipient Entity
DENOVA RESEARCH
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202459850
Principal investigator 1 Eli Lilly and Company $67,200.00 02/18/2025 Non-covered Recipient Entity
DENOVA RESEARCH
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187878721
Principal investigator 1 Janssen Research & Development, LLC $2,233.00 02/10/2025 Non-covered Recipient Entity
DENOVA RESEARCH
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175337562
Principal investigator 1 ABBVIE INC. $13,125.60 02/06/2025 Non-covered Recipient Entity
DENOVA RESEARCH
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202447062
Principal investigator 1 ABBVIE INC. $12,936.60 02/06/2025 Non-covered Recipient Entity
DENOVA RESEARCH
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202447066
Principal investigator 1 ABBVIE INC. $2,274.40 02/06/2025 Non-covered Recipient Entity
DENOVA RESEARCH
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202447070
Principal investigator 1 Amgen Inc. $42,285.14 01/27/2025 Non-covered Recipient Entity
DENOVA RESEARCH
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246640685
Principal investigator 1 Eli Lilly and Company $3,192.57 01/27/2025 Non-covered Recipient Entity
DENOVA RESEARCH
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187878187